| human | Q5 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 155990314 |
| P2038 | ResearchGate profile ID | Annegien_Broeks |
| P214 | VIAF ID | 290007617 |
| P10832 | WorldCat Entities ID | E39PBJj8WJKg9FKjQWXHd3bTpP |
| P27 | country of citizenship | Kingdom of the Netherlands | Q29999 |
| P106 | occupation | researcher | Q1650915 |
| P5008 | on focus list of Wikimedia project | gender gap on Dutch Wikipedia | Q60687720 |
| P21 | sex or gender | female | Q6581072 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
| Q28943455 | A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3) |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q45286458 | ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population |
| Q34145071 | ATM-heterozygous germline mutations contribute to breast cancer-susceptibility |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q51051999 | Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q54582432 | Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q91117991 | Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q37315121 | Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q51621180 | Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q33627208 | Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q57471717 | Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q37377920 | Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features |
| Q27851413 | Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium |
| Q44846681 | ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy |
| Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q46247419 | Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases |
| Q48002614 | Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q57319538 | FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma |
| Q37307305 | Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q45269491 | From gene to disease; ataxia telangiectasia |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q40137431 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium |
| Q62583135 | Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q47401275 | IVS10-6T>G, an ancient ATM germline mutation linked with breast cancer |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q34714085 | Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing |
| Q35794366 | Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study |
| Q38677974 | Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers |
| Q53555163 | In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. |
| Q42628531 | Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
| Q34046731 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q59539067 | Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q43809547 | Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q42466606 | Radiation-associated breast tumors display a distinct gene expression profile |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q47439682 | Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations |
| Q53176639 | Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. |
| Q47788586 | Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease |
| Q33593016 | Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies |
| Q38860651 | Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma |
| Q91258149 | The circular RNome of primary breast cancer |
| Q37147694 | The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype |
| Q29614637 | The landscape of cancer genes and mutational processes in breast cancer |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q36267279 | The spectrum of ATM missense variants and their contribution to contralateral breast cancer |
| Q39996262 | Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.